What's new

Draft Reflection paper on linking to electronic product...

Mar 31, 2025 0

Draft Reflection paper on linking to electronic product information (ePI) from E...

Electronic product information (ePI)

Electronic product information (ePI)

Mar 31, 2025 0

Electronic product information (ePI)

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 31, 2025 0

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab d...

Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 31, 2025 0

Human medicines European public assessment report (EPAR): Amgevita, adalimumab, ...

Human medicines European public assessment report (EPAR): MicardisPlus, Date of authorisation: 19/04/2002, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 31, 2025 0

Human medicines European public assessment report (EPAR): MicardisPlus, Date of ...

Human medicines European public assessment report (EPAR): Nplate, romiplostim, Date of authorisation: 04/02/2009, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 31, 2025 0

Human medicines European public assessment report (EPAR): Nplate, romiplostim, D...

Human medicines European public assessment report (EPAR): Efmody, hydrocortisone, Date of authorisation: 27/05/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 31, 2025 0

Human medicines European public assessment report (EPAR): Efmody, hydrocortisone...

Human medicines European public assessment report (EPAR): Heplisav B, hepatitis B surface antigen, Date of authorisation: 18/02/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 31, 2025 0

Human medicines European public assessment report (EPAR): Heplisav B, hepatitis ...

Human medicines European public assessment report (EPAR): Rukobia, fostemsavir, Date of authorisation: 04/02/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 31, 2025 0

Human medicines European public assessment report (EPAR): Rukobia, fostemsavir, ...

EVVet3 EVWeb Production - Release notes

Mar 31, 2025 0

EVVet3 EVWeb Production - Release notes

European Surveillance of Veterinary Antimicrobial Consumption (ESVAC): 2009 - 2023

European Surveillance of Veterinary Antimicrobial Consu...

Mar 31, 2025 0

European Surveillance of Veterinary Antimicrobial Consumption (ESVAC): 2009 - 2023

European Sales and Use of Antimicrobials for Veterinary Medicine (ESUAvet) annual surveillance reports

European Sales and Use of Antimicrobials for Veterinary...

Mar 31, 2025 0

European Sales and Use of Antimicrobials for Veterinary Medicine (ESUAvet) annua...

European sales and use of antimicrobials for veterinary...

Mar 31, 2025 0

European sales and use of antimicrobials for veterinary medicine: Annual surveil...

Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 28, 2025 0

Human medicines European public assessment report (EPAR): Lydisilka, estetrol,dr...

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 53, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 28, 2025 0

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Da...

Human medicines European public assessment report (EPAR): Ontilyv, opicapone, Date of authorisation: 21/02/2022, Revision: 2, Status: Lapsed

Human medicines European public assessment report (EPAR...

Mar 28, 2025 0

Human medicines European public assessment report (EPAR): Ontilyv, opicapone, Da...

Human medicines European public assessment report (EPAR): Kevzara, sarilumab, Date of authorisation: 23/06/2017, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 28, 2025 0

Human medicines European public assessment report (EPAR): Kevzara, sarilumab, Da...

Human medicines European public assessment report (EPAR): Nexavar, sorafenib, Date of authorisation: 19/07/2006, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 28, 2025 0

Human medicines European public assessment report (EPAR): Nexavar, sorafenib, Da...

Human medicines European public assessment report (EPAR): Ofev, nintedanib, Date of authorisation: 14/01/2015, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 28, 2025 0

Human medicines European public assessment report (EPAR): Ofev, nintedanib, Date...

Human medicines European public assessment report (EPAR): Incruse Ellipta (previously Incruse), umeclidinium bromide, Date of authorisation: 28/04/2014, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 28, 2025 0

Human medicines European public assessment report (EPAR): Incruse Ellipta (previ...

History of EMA

Mar 28, 2025 0

History of EMA

Human medicines European public assessment report (EPAR): Winrevair, Sotatercept, Date of authorisation: 22/08/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 28, 2025 0

Human medicines European public assessment report (EPAR): Winrevair, Sotatercept...

EMA’s 30th anniversary scientific conference - Medicines, regulation and the future, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 25 June 2025, 10:00 (CEST) to 25 June 2025, 16:00 (CEST)

EMA’s 30th anniversary scientific conference - Medicine...

Mar 28, 2025 0

EMA’s 30th anniversary scientific conference - Medicines, regulation and the fut...

Human medicines European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta), umeclidinium, Date of authorisation: 20/03/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 28, 2025 0

Human medicines European public assessment report (EPAR): Rolufta Ellipta (previ...

13
14
15
16
17

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.